The Danish drugmaker’s numerous development tasks west of Paris shall be accomplished by the tip of 2028 for a major improve manufacturing of its present and future product portfolio inside severe power illnesses.
“With this, we will – over the coming years – increase our production capacity to be prepared for the increased demand for our medicines and future innovations from our pipeline,” Novo Nordisk mentioned on Thursday.
It added that the investment provides capability for GLP-1 merchandise, referring to the energetic ingredient in its pioneering weight-loss drug Wegovy and in the lower-dose model Ozempic, which has additionally been used for weight reduction outdoors of its accepted use in opposition to diabetes.
The French authorities has pitched the growth plan as an indication of newly restored French industrial competitiveness.
The investment in Chartres, the place Novo already employs practically 2,000 individuals making pre-filled injector pens and insulin, will lead to the creation of 500 jobs, the corporate mentioned.
Novo’s investment mirrors the same transfer by U.S. rival Eli Lilly, which final week laid out plans to construct a $2.5 billion manufacturing web site in Germany in response to soaring demand for its new diabetes and weight problems therapies.